Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 3:25 PM ET

Biotechnology

Company Overview of OvaScience, Inc.

Company Overview

OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries;...

215 First Street

Suite 240

Cambridge, MA 02142

United States

Founded in 2011

52 Employees

Phone:

617-500-2802

Key Executives for OvaScience, Inc.

Co-Founder, Chief Executive Officer and Director
Age: 38
President
Total Annual Compensation: $106.3K
Compensation as of Fiscal Year 2013.

OvaScience, Inc. Key Developments

OvaScience, Inc. - Special Call

OvaScience, Inc. - Special Call

OvaScience, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

OvaScience, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. Net loss for the three months ended December 31, 2014 was $18.9 million or $0.79 per share, as compared to net loss of $11.0 million or $0.64 per share, for the three months ended December 31, 2013. Loss from operations was $18.289 million against $11.013 million a year ago. Net loss for the year ended December 31, 2014 was $49.5 million or $2.19 per share, as compared to net loss of $29.0 million, or $1.80 per share, for the year ended December 31, 2013. The annual increase is primarily attributable to stock-based compensation, planned higher personnel costs, and costs associated with the launch of the AUGMENT treatment in select international regions. Loss from operations was $47.933 million against $29.134 million a year ago.

OvaScience, Inc. Presents at Credit Suisse One-on-One Healthcare Conference, Mar-03-2015

OvaScience, Inc. Presents at Credit Suisse One-on-One Healthcare Conference, Mar-03-2015 . Venue: London, United Kingdom.

Similar Private Companies By Industry

Company Name Region
Life Sciences Advanced Technologies, Inc. United States
Ravgen, Inc. United States
OnCore Biopharma, Inc. United States
Everon Biosciences, Inc. United States
Third Wave Agbio Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OvaScience, Inc., please visit www.ovascience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.